Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines

被引：0
|
作者：
Hofer, V. [1 ]
Wobser, M. [1 ]
Maurus, K. [2 ]
Houben, R. [1 ]
Schrama, D. [1 ]
机构：
[1] Uniklinikum Wurzburg, Wurzburg, Germany
[2] Univ Wurzburg, Pathol, Wurzburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP105
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [1] Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines
    Hofer, Vivian
    Wobser, Marion
    Maurus, Katja
    Houben, Roland
    Schrama, David
    Goebeler, Matthias
    Rosenwald, Andreas
    EUROPEAN JOURNAL OF CANCER, 2023, 190 : S25 - S26
  • [2] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
    Moritz, R. K. C.
    Patsinakidis, N.
    Terras, S.
    Moellenhoff, K.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921
  • [3] Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma
    Lewis, D. J.
    Kim, Y. H.
    Duvic, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 302 - 303
  • [4] Use of brentuximab vedotin for recalcitrant CD30+cutaneous T cell lymphoma
    Freeman, E. E.
    Tawa, M.
    Dorosario, A. A.
    Kupper, T. S.
    Fisher, D. C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S94 - S94
  • [5] Brentuximab vedotin — a new standard for cutaneous T-cell lymphoma
    David Killock
    Nature Reviews Clinical Oncology, 2017, 14 : 460 - 460
  • [6] Brentuximab vedotin in T-cell lymphoma
    Van der Weyden, Carrie
    Dickinson, Michael
    Whisstock, James
    Prince, H. Miles
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 5 - 19
  • [7] CD30-Positive Cutaneous T-Cell Lymphoma and Response to Brentuximab Vedotin: 2 Illustrative Cases
    Mody, Kabir
    Wallace, Jill S.
    Stearns, Diane M.
    Bowers, George
    Lacy, Shannon R.
    Levy, Norman B.
    Zug, Kathryn A.
    Lansigan, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 319 - 323
  • [8] Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management
    Scarisbrick, Julia J.
    FUTURE ONCOLOGY, 2017, 13 (27) : 2405 - 2411
  • [9] Brentuximab vedotin - a highly potent Therapy for cutaneous T-Cell Lymphoma
    Pax, A. T.
    Stadler, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 (12): : E6 - E6
  • [10] Brentuximab vedotin in systemic T-cell lymphoma
    Oki, Yasuhiro
    Younes, Anas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 623 - 632
12345